Haemolytic-uraemic syndrome: deficiency of plasma factor(s) regulating prostacyclin activity?
It is suggested that patients with the haemolytic-uraemic syndrome and related disorders (such as thrombotic thrombocytopenic purpura) lack a plasma factor which stimulates prostacyclin (P.G.I2) activity. Normal plasma would supply the missing factor and is a rational treatment for some life-threatening symptoms (thrombocytopenia, haemolytic anaemia, hypertension) of this syndrome.
D000743:Anemia, Hemolytic / Q000097:blood / Q000628:therapy; D000925:Anticoagulants; D011464:Epoprostenol / Q000502:physiology*; D006463:Hemolytic-Uremic Syndrome / Q000097:blood / Q000628:therapy*; D006801:Humans; D006977:Hypertension, Renal / Q000097:blood / Q000628:therapy; D010949:Plasma / Q000502:physiology*; D010956:Plasmapheresis; D010974:Platelet Aggregation; D011453:Prostaglandins / Q000502:physiology*; D013921:Thrombocytopenia / Q000097:blood / Q000628:therapy
D000925:Anticoagulants; D011453:Prostaglandins; D011464:Epoprostenol